Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]FluorThanatrace PET/CT in Pancreatic Cancer
NCT03492164Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Mar 2018
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 3 years. Started Mar 2018; status: terminated.
Beyond the preview
Go deeper on NCT03492164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492164.